Company Overview of Delinia, Inc.
Delinia, Inc., a biotechnology company, focuses on developing novel therapeutics for the treatment of autoimmune diseases. Its lead program is a molecule that potentiates and expands regulatory T cells (Tregs), which are critical to maintaining self-tolerance and immune system homeostasis. The company was incorporated in 2014 and is based in San Francisco, California.
953 Indiana Street
San Francisco, CA 94107
Founded in 2014
Key Executives for Delinia, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
January 26, 2017
September 14, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Delinia, Inc., please visit www.deliniabio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.